A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study.
By C. Pappone, G. Augello, S. Sala, F. Gugliotta, G. Vicedomini, S. Gulletta, G. Paglino, P. Mazzone, N. Sora, I. Greiss and 6 more. Journal of the American College of Cardiology, 2006
713 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/cc7cb8668b65b88bda9f9f9c01946d7a85ef9b4a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. (2010, methodology): “In prior randomized trials of catheter ablation vs ADT for paroxysmal AF, 1 year freedomfromrecurrentAFwasreported in56%to89%ofpatients treatedbycatheterablation.(14-16) This rangeofoutcomes may reflect differences in patient selection, intensityof rhythmmonitoringand auditingduringfollow-up,endpoin”
- Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. (2014, neutral): “2 Coronary artery disease 10 (11) 10 (16) 0.”
- 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design (2012, background): “A 1- to 7-day Holter monitor is an effective way to identify frequent asymptomatic recurrences of AF [111, 325, 392, 455].”
- 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation (2017, neutral): “In addition to the trials for FDA approval listed in Table 7, four of these trials exclusively enrolled patients with paroxysmal (or “early persistent”) AF, three trials enrolled only patients with persistent AF, and three trials enrolled patients with either AF pattern.(261,462,684,733,1025,1026,10”